Abstracts tagged "Cognitive dysfunction"

Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Erik Anderson¹, Joanna Fishbein², Joseph Hong², Julien Roeser³, Richard Furie⁴, Cynthia Aranow², Bruce Volpe², Betty Diamond⁵ and Meggan Mackay⁶, ¹Feinstein Institutes for Medical Research, New York, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Northwell Health, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 1819 • ACR Convergence 2020
Altered Brain Functional Connectivity in Systemic Lupus Erythematosus
Michelle Barraclough¹, Shane McKie², Benjamin Parker¹, Alan Jackson³, Rebecca Elliott⁴ and Ian Bruce⁵, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, ⁴Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is very prevalent in SLE and significantly affects quality of life. Altered functional brain mechanisms are associated with CD in SLE.…
Abstract Number: 0026 • ACR Convergence 2020
A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment
Valerie Aloush¹, Chen Yaalon², Sheer Raev², Noy Sobol², Jacob Ablin¹, Ran Shorer³ and Odelia Elkana², ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Academic College Tel Aviv Jaffa, Tel Aviv, Israel, ³Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: In a previous study, we showed that the subjective item assessing cognitive impairment (SSS-Cog) for fibromyalgia (FM) did not correlate with objective cognitive measures.…
Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
Sara Ganhão ¹, Mariana Rodrigues², Beatriz Silva ¹, Francisca Aguiar ¹, Margarida Figueiredo-Braga ¹ and Iva Brito ¹, ¹Centro Hospitalar de São João, Oporto, Portugal, ²Porto, Portugal
Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 1612 • 2019 ACR/ARP Annual Meeting
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough ¹, Shane McKie ², Benjamin Parker ¹, Alan Jackson ³, Philip Pemberton ⁴, Rebecca Elliott ⁵ and Ian Bruce⁶, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, United Kingdom, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University NHS Foundation Trust, Manchester, ⁵Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is a common symptom in systemic lupus erythematosus (SLE), that significantly affects quality of life but there are limited treatment options…
Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Renata Rosa¹, Michelle Remião Ugolini-Lopes ², Ana Paula Gandara ², Kenia Campanholo ², Livia Dutra ³ and Danieli Andrade ⁴, ¹Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Brazil, ³Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…
Abstract Number: 259 • 2018 ACR/ARHP Annual Meeting
Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia
Sebastian Moyano¹, Waleska Berrios², Ignacio Javier Gandino³, Angel Golimstok⁴, Javier Rosa⁵ and Enrique R Soriano⁶, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ⁴Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁶Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Chronic diseases involve cognitive aspects. Attention deficit hyperactivity disorder (ADHD) is a chronic condition, marked by persistent inattention, impaired concentration, hyperactivity, impulsivity, emotional lability,…
Abstract Number: 409 • 2018 ACR/ARHP Annual Meeting
Unique Skeletal Muscle Relaxant Tolperisone in a Crossover Driving Simulation Study: No Evidence of Sedation Compared to Cyclobenzaprine and Placebo
Judy Caron¹, Thomas Wessel² and Gary Kay³, ¹Drug Development, Neurana Pharmaceuticals, San Diego, CA, ²Medical, Neurana Pharmaceuticals, San Diego, CA, ³Drug Development, Cognitive Research Corporation, St Petersburg, FL
Background/Purpose: Tolperisone is a centrally-acting muscle relaxant being developed in the US as a treatment for acute and painful symptoms of neck and low back…
Abstract Number: 487 • 2018 ACR/ARHP Annual Meeting
Cognitive Impairment in Rheumatoid Arthritis Patients: A Case-Control Study
Beatriz Rizkallah Alves¹, BRUNO KUSZNIR VITTURI², BRUNO AZEREDO COUTINHO NASCIMENTO³, FELIPE SOBOLEWSKI CARNEIRO DE CAMPOS³ and Dawton Yukito Torigoe³, ¹rheumatology, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil, ²rheumatology, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil, ³Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. Extra-articular manifestations of RA can occur in about 40% of patients, either…
Abstract Number: 723 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Identifying patients with Systemic Lupus Erythematosus related cognitive impairment (SLE-CI) is critical as SLE-CI can negatively affect employment, quality of life, and disease self-management.…
Abstract Number: 770 • 2018 ACR/ARHP Annual Meeting
Cognitive Function Trajectories Are Associated with the Depressive Symptoms Trajectories in SLE over Time
Zahi Touma¹, Jiandong Su¹ and Patricia Katz², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of California San Francisco, San Francisco, CA
Background/Purpose: We have shown that cognitive function followed particular trajectories over time in SLE, with some patients having persistently low scores and others normal scores.…
Abstract Number: 782 • 2018 ACR/ARHP Annual Meeting
Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort
Chrisanna Dobrowolski¹, Lisa Engel², Robin Green³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Carmela Tartaglia⁵, Nicole Anderson², Kenneth Colosimo², Michelle Vitti², Dennisse Bonilla², Joan E. Wither⁶, Marvin J. Fritzler⁷, Dorcas Beaton⁸ and Zahi Touma², ¹University of Ottawa, Ottawa, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are commonly affected by cognitive impairment (CI), with a meta-analysis finding a prevalence of 38%. Despite this high…
Abstract Number: 1667 • 2018 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Approximately 38% of adults living with Systemic Lupus Erythematosus (SLE) experience cognitive impairment (CI) that can detrimentally affect employment, disease self-management, and quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].